[
  {
    "ts": null,
    "headline": "Biogen Spotlights Lupus Pipeline at Piper Sandler Symposium: Litifilimab, Dapirolizumab in Focus",
    "summary": "Biogen (NASDAQ:BIIB) outlined its immunology and neurology development priorities during a virtual symposium hosted by Piper Sandler, with Dr. Diana Gallagher, head of clinical development for MS, immunology, and Alzheimer’s disease, discussing late-stage lupus programs and earlier-stage pipeline ef",
    "url": "https://finnhub.io/api/news?id=b8efab89800747bddee6936691d8f8e8615b97ee1487e69bbb6d5db82748a27b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770999744,
      "headline": "Biogen Spotlights Lupus Pipeline at Piper Sandler Symposium: Litifilimab, Dapirolizumab in Focus",
      "id": 139086794,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen (NASDAQ:BIIB) outlined its immunology and neurology development priorities during a virtual symposium hosted by Piper Sandler, with Dr. Diana Gallagher, head of clinical development for MS, immunology, and Alzheimer’s disease, discussing late-stage lupus programs and earlier-stage pipeline ef",
      "url": "https://finnhub.io/api/news?id=b8efab89800747bddee6936691d8f8e8615b97ee1487e69bbb6d5db82748a27b"
    }
  },
  {
    "ts": null,
    "headline": "Wedbush Lifts PT on Biogen Inc. (BIIB) to $187 From $178 – Here’s Why",
    "summary": "Biogen Inc. (NASDAQ:BIIB) is one of the best medical research stocks to buy according to hedge funds. On February 10, Wedbush lifted the price target on Biogen Inc. (NASDAQ:BIIB) to $187 from $178, maintaining a Neutral rating on the shares. The firm told investors that Biogen Inc. (NASDAQ:BIIB) delivered another top-/bottom-line beat in its fiscal Q4 […]",
    "url": "https://finnhub.io/api/news?id=f76090e0231e8487ec957b9810e90f7b2ca88c472104d9c8c2d9a2f0a2978e7d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770994660,
      "headline": "Wedbush Lifts PT on Biogen Inc. (BIIB) to $187 From $178 – Here’s Why",
      "id": 139085267,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen Inc. (NASDAQ:BIIB) is one of the best medical research stocks to buy according to hedge funds. On February 10, Wedbush lifted the price target on Biogen Inc. (NASDAQ:BIIB) to $187 from $178, maintaining a Neutral rating on the shares. The firm told investors that Biogen Inc. (NASDAQ:BIIB) delivered another top-/bottom-line beat in its fiscal Q4 […]",
      "url": "https://finnhub.io/api/news?id=f76090e0231e8487ec957b9810e90f7b2ca88c472104d9c8c2d9a2f0a2978e7d"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Inc. (BIIB) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript",
    "summary": "Biogen Inc. (BIIB) Piper Sandler Virtual Novel Targets in Immunology Symposium February 13, 2026 10:30 AM ESTCompany ParticipantsDiana Gallagher - Head of...",
    "url": "https://finnhub.io/api/news?id=0ec9df3fdcbecad5cfa8b9bb3cce0d809349c08902283a8ada063ac139ac8210",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770988066,
      "headline": "Biogen Inc. (BIIB) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript",
      "id": 139086972,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "Biogen Inc. (BIIB) Piper Sandler Virtual Novel Targets in Immunology Symposium February 13, 2026 10:30 AM ESTCompany ParticipantsDiana Gallagher - Head of...",
      "url": "https://finnhub.io/api/news?id=0ec9df3fdcbecad5cfa8b9bb3cce0d809349c08902283a8ada063ac139ac8210"
    }
  },
  {
    "ts": null,
    "headline": "Biogen's (NASDAQ:BIIB) Soft Earnings Don't Show The Whole Picture",
    "summary": "Soft earnings didn't appear to concern Biogen Inc.'s ( NASDAQ:BIIB ) shareholders over the last week. We did some...",
    "url": "https://finnhub.io/api/news?id=9017e2012e1a6777deea0b0df80f341d48d59f8d0d001a767ad5b1e4165b036d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770981802,
      "headline": "Biogen's (NASDAQ:BIIB) Soft Earnings Don't Show The Whole Picture",
      "id": 139079852,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Soft earnings didn't appear to concern Biogen Inc.'s ( NASDAQ:BIIB ) shareholders over the last week. We did some...",
      "url": "https://finnhub.io/api/news?id=9017e2012e1a6777deea0b0df80f341d48d59f8d0d001a767ad5b1e4165b036d"
    }
  },
  {
    "ts": null,
    "headline": "Lyell starts first-of-its-kind CAR-T trial; New coalition aims to boost European biotechs",
    "summary": "Lyell’s trial will test its experimental cancer cell therapy directly against marketed counterparts. Elsewhere, Biogen swapped board chairs and venture firms are joining up at a “pivotal time” for Europe.",
    "url": "https://finnhub.io/api/news?id=b7a42247ade0ef86cba3e917ba79c0636a709baa7a617f626422c06f019c1874",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770980400,
      "headline": "Lyell starts first-of-its-kind CAR-T trial; New coalition aims to boost European biotechs",
      "id": 139086795,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Lyell’s trial will test its experimental cancer cell therapy directly against marketed counterparts. Elsewhere, Biogen swapped board chairs and venture firms are joining up at a “pivotal time” for Europe.",
      "url": "https://finnhub.io/api/news?id=b7a42247ade0ef86cba3e917ba79c0636a709baa7a617f626422c06f019c1874"
    }
  },
  {
    "ts": null,
    "headline": "The 5 Most Interesting Analyst Questions From Biogen’s Q4 Earnings Call",
    "summary": "Biogen’s fourth-quarter results were received positively by the market, as the company exceeded Wall Street’s revenue and non-GAAP profit expectations despite a year-over-year decline in sales. Management attributed performance to robust growth in its newer product portfolio, particularly Lekembi, Skyclaris, Xerxuve, and Calcadi, which collectively surpassed $1 billion in annual revenue. CEO Christopher Viehbacher pointed to successful expansion of VUMERITY within the multiple sclerosis segment",
    "url": "https://finnhub.io/api/news?id=1bb9be31721ae383c7cd1e7976fada891a1f6cd84776a36b9d3ac3b5e2c0cd40",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770960998,
      "headline": "The 5 Most Interesting Analyst Questions From Biogen’s Q4 Earnings Call",
      "id": 139079211,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen’s fourth-quarter results were received positively by the market, as the company exceeded Wall Street’s revenue and non-GAAP profit expectations despite a year-over-year decline in sales. Management attributed performance to robust growth in its newer product portfolio, particularly Lekembi, Skyclaris, Xerxuve, and Calcadi, which collectively surpassed $1 billion in annual revenue. CEO Christopher Viehbacher pointed to successful expansion of VUMERITY within the multiple sclerosis segment",
      "url": "https://finnhub.io/api/news?id=1bb9be31721ae383c7cd1e7976fada891a1f6cd84776a36b9d3ac3b5e2c0cd40"
    }
  },
  {
    "ts": null,
    "headline": "1 Unpopular Stock That Deserves a Second Chance and 2 We Find Risky",
    "summary": "When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.",
    "url": "https://finnhub.io/api/news?id=8d45fd8247c8475e803a7fa36d776d5b9e21558cad1adec0c875fa8b10c3f897",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770957677,
      "headline": "1 Unpopular Stock That Deserves a Second Chance and 2 We Find Risky",
      "id": 139089939,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.",
      "url": "https://finnhub.io/api/news?id=8d45fd8247c8475e803a7fa36d776d5b9e21558cad1adec0c875fa8b10c3f897"
    }
  }
]